Ethical Challenges of Preexposure Prophylaxis for HIV

Publication Year:
2012
Mentions 1
Blog Mentions 1
Social Media 1
Tweets 1
Repository URL:
https://scholarship.law.georgetown.edu/ois_papers/43; https://scholarship.law.georgetown.edu/facpub/1003
Author(s):
Jay, Jonathan S.; Gostin, Lawrence O.
Tags:
HIV/AIDS; truvada; preexposure prophylaxis; ethical challenges; treatment vs. prevention; equitable distribution of HIV drugs; Bioethics and Medical Ethics; Health Law and Policy; Public Health; Public Policy
Most Recent Tweet View All Tweets
Most Recent Blog Mention
article description
On July 16, 2012, emtricitabine/tenofovir (Truvada) became the first drug approved by the US Food and Drug Administration for preexposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) for adults at high risk. While PrEP appears highly effective with consistent adherence, effective implementation poses ethical challenges for the medical and public health community. For PrEP users, it is necessary to maintain adherence, safe sex practices, and routine HIV testing and medical monitoring, to maximize benefits and reduce risks. On a population level, comparative cost-effectiveness should guide priority-setting, while safety measures must address drug resistance concerns without burdening patients' access. Equitable distribution will require addressing the needs of underserved populations, women (for whom efficacy data are mixed) and people living in developing countries with high HIV incidence; meanwhile, it is necessary to consider the fair use of drugs for treatment vs. prevention and the appropriate design of new HIV prevention studies.